Scinovex
review Open AccessTop 1% cited

The Global Landscape of EBV-Associated Tumors

Frontiers in Oncology · 2019 · Vol. 9 · pp. 713–713
Claire Shannon‐LoweAlan B. Rickinson

Abstract

Epstein-Barr virus (EBV), a gamma-1 herpesvirus, is carried as a life-long asymptomatic infection by the great majority of individuals in all human populations. Yet this seemingly innocent virus is aetiologically linked to two pre-malignant lymphoproliferative diseases (LPDs) and up to nine distinct human tumors; collectively these have a huge global impact, being responsible for some 200,000 new cases of cancer arising worldwide each year. EBV replicates in oral epithelium but persists as a latent infection within the B cell system and several of its diseases are indeed of B cell origin; these include B-LPD of the immunocompromised, Hodgkin Lymphoma (HL), Burkitt Lymphoma (BL), Diffuse Large B cell Lymphoma (DLBCL) and two rarer tumors associated with profound immune impairment, plasmablastic lymphoma (PBL) and primary effusion lymphoma (PEL). Surprisingly, the virus is also linked to tumors arising in other cellular niches which, rather than being essential reservoirs of virus persistence <i>in vivo</i>, appear to represent rare cul-de-sacs of latent infection. These non-B cell tumors include LPDs and malignant lymphomas of T or NK cells, nasopharyngeal carcinoma (NPC) and gastric carcinoma of epithelial origin, and leiomyosarcoma, a rare smooth muscle cell tumor of the immunocompromised. Here we describe the main characteristics of these tumors, their distinct epidemiologies, histological features and degrees of EBV association, then consider how their different patterns of EBV latency may reflect the alternative latency programmes through which the virus first colonizes and then persists in immunocompetent host. For each tumor, we discuss current understanding of EBV's role in the oncogenic process, the identity (where known) of host genetic and environmental factors predisposing tumor development, and the recent evidence from cancer genomics identifying somatic changes that either complement or in some cases replace the contribution of the virus. Thereafter we look for possible connections between the pathogenesis of these apparently different malignancies and point to new research areas where insights may be gained.

Funding

  • Medical Research Council
Citations
449
FWCI
23.71
field-weighted impact
References
206
Percentile
100%
vs. same field & year
Citations per year
References
Epstein–Barr virus: 40 years on
Nature reviews. Cancer · 2004 · 2,185 citations
A sarcoma involving the jaws in african children
British journal of surgery · 1958 · 1,323 citations
The global health burden of infection‐associated cancers in the year 2002
International Journal of Cancer · 2006 · 2,920 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

The Global Landscape of EBV-Associated Tumors · Scinovex